Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 17/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.49 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.45 |
| ▸ | WNT1 | P04628 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5024997 | 0.86 | ADORA2A (0.53) | ADORA2AADORA1MKNK1WNT1GSK3B | |
| SCHEMBL5016080 | 0.85 | ADORA2A (0.53) | ADORA2AADORA1MKNK1WNT1GSK3B | |
| SCHEMBL8287558 | 0.85 | ADORA2A (0.73) | ADORA2AADORA1 | |
| SCHEMBL5022961 | 0.84 | ADORA2A (0.56) | ADORA2AADORA1 | |
| SCHEMBL4962442 | 0.83 | ADORA2A (0.55) | ADORA2AADORA1 | |
| SCHEMBL5022903 | 0.82 | ADORA2A (0.54) | ADORA2AADORA1 | |
| SCHEMBL5022422 | 0.82 | ADORA2A (0.53) | ADORA2AADORA1 | |
| SCHEMBL5026352 | 0.81 | ADORA2A (0.43) | ADORA2AADORA1MKNK1WNT1GSK3B | |
| SCHEMBL5022258 | 0.81 | POLB (0.43) | ADORA2AADORA1MKNK1 | |
| SCHEMBL5026311 | 0.80 | ADORA2A (0.61) | ADORA2AADORA1MKNK1WNT1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080058356-A1 | 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| EP-1697351-A1 | 2,6-BISHETEROARYL-4-AMINOPYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS | Almirall Prodesfarma AG (CH) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005058883-A1 | 2, 6 BISHETEROARYL-4-AMINOPYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS | ALMIRALL PRODESFARMA AG (CH) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058356-A1 | 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA1 3/4885MKNK1 3055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.